Cargando…
Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Autores principales: | Ismail, R.K., van Breeschoten, J., Wouters, M.W.J.M., van Dartel, M., van der Flier, S., Reyners, A.K.L., de Graeff, P., Pasmooij, A.M.G., de Boer, A., Broekman, K.E., Hilarius, D.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073288/ https://www.ncbi.nlm.nih.gov/pubmed/35190238 http://dx.doi.org/10.1016/j.breast.2022.01.011 |
Ejemplares similares
-
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: Ismail, R.K., et al.
Publicado: (2021) -
Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis
por: Ismail, Rawa Kamaran, et al.
Publicado: (2022) -
Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
por: Regan, Meredith M.
Publicado: (2022) -
Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023) -
Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)